Las últimas noticias médicas de WillebrandXPERT
Versión en línea
WillebrandXPERT
Bienvenido,
Leerá debajo las últimas publicaciones científicas de las principales revistas especializada en su área de competencia.
Von Willebrand Academy - Ep.4
Publicado el  Jueves, 30 de julio de 2026
Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome.
American Journal of Hematology (2026).
Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history...
Versión HTML |  Versión PDF  |  Versión imprimible
Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.
Haemophilia (2026).
Von Willebrand disease (VWD) is the most common inheritedbleeding disorder, but its true burden remains difficult to quan-tify because many affected individuals are never diagnosed orare diagnosed only...
Versión HTML |  Versión PDF  |  Versión imprimible
Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States
Blood advances (July 2026)
Von Willebrand factor (VWF) concentrate prophylaxis is recommended for patients with severe von Willebrand disease (VWD) or VWD with frequent bleeding symptoms but remains underutilized, in part due to...
Versión HTML |  Versión PDF  |  Versión imprimible
An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3.
Haemophilia (2026).
Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor-initiated coagulation through FXa-dependent inhibition of the tissue factor-FVIIa complex, has emerged as a promising target for...
Versión HTML |  Versión PDF  |  Versión imprimible
Inicio  |  Noticias  |  Archivos
Informar a un colega | Editar mi perfil | Darse de baja | Fuentes y criterios de la información
GNM Healthcare